Recurrent respiratory papillomatosis represents the first indication that Stressgen Biotechnologies Corp. intends to pursue with its drug HspE7, based on positive Phase II data released this week. (BioWorld Today)

Domantis Ltd. raised US$33 million in a Series B financing that could take the company into clinical trials with its lead domain antibody (dAb) therapeutics. (BioWorld Today)

Two more companies placed convertible notes with the same goal in mind: pay off old debt with new debt, but under better terms. (BioWorld Today)